Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) reached a new 52-week low during trading on Tuesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 7000 shares trading hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Trading Down 50.0 %
The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The firm has a 50-day moving average of C$0.01 and a 200 day moving average of C$0.01. The company has a market cap of C$663,150.00, a P/E ratio of -0.50 and a beta of -0.02.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Stories
- Five stocks we like better than Aequus Pharmaceuticals
- How to Evaluate a Stock Before BuyingÂ
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- What Are Dividend Achievers? An Introduction
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- What Is WallStreetBets and What Stocks Are They Targeting?
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
